Catabasis names VP, development
This article was originally published in Scrip
Catabasis Pharmaceuticals, which develops drugs for severe lipid disorders and rare diseases, has named Dr Angelika Fretzen vice-president of development. Prior to joining Catabasis Dr Fretzen was vice-president of pharmaceutical chemistry and development at Ironwood Pharmaceuticals. She has been responsible for discovery and development programs for small molecules and peptides in a variety of different disease areas and prior to joining Ironwood Dr Fretzen was an Alexander von Humboldt Fellow in the department of chemistry and chemical biology at Harvard University.